10x Genomics, Inc. has recently released its 10-K report, providing a detailed insight into the company's financial condition and operational performance. The Pleasanton, California-based life science technology company specializes in developing and selling instruments, consumables, and software for analyzing biological systems across various regions, including the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's product portfolio includes the Chromium platform for analyzing individual biological components, the Visium platform for spatial gene expression, and the Xenium Analyzer for detecting and preserving the cellular location of RNA targets in tissue sections. Additionally, 10x Genomics offers post-warranty service contracts for its instruments.
In the 10-K report, 10x Genomics highlighted its acquisition of Scale Biosciences, Inc., a single-cell genomics technology company, in August 2025. The acquisition involved an upfront payment of $9.2 million in cash and $13.5 million in shares of 10x Genomics' Class A common stock. Further payments of up to $30.0 million may be made in the future, contingent on meeting certain milestones. The transaction was accounted for as an asset acquisition due to the concentration of the fair value of the assets acquired in the developed technology.
The report also delved into key business metrics, including cumulative instruments sold and total consumables reactions. As of December 31, 2025, 10x Genomics had sold 6,477 Chromium (Single Cell) instruments, 1,015 Visium (Spatial) instruments, and 554 Xenium (Spatial) instruments since inception. The company's total consumable reactions for the year ended December 31, 2025, amounted to 424,000, reflecting the reagent setups needed to perform experiments using its solutions.
10x Genomics outlined several key factors affecting its performance, including instrument sales, recurring consumable revenue, pricing changes, revenue mix and gross margin, and continued investment in growth. The company emphasized its focus on driving instrument sales as an indicator of current business success and a leading indicator of likely future sales of consumables. Additionally, it detailed its efforts to expand sales globally, adjust instrument prices, and enhance technology and applications for life sciences research to support instrument sales.
The 10-K report also provided insight into the company's revenue components, including products and services revenue, license and royalty revenue, cost of products and services revenue, gross profit, and gross margin. 10x Genomics generates the majority of its revenue through the sale of instruments and consumables to customers, with a portion of revenue stemming from instrument service agreements and license and royalty agreements with third parties.
Today the company's shares have moved -3.21% to a price of $20.52. For more information, read the company's full 10-K submission here.
